A multicentre, prospective, longitudinal study evaluated whether patients’ blood lymphocyte profile before the initiation of alemtuzumab treatment may help predict the development of later autoimmunity. The Spanish study included 54 relapsing-remitting MS (RRMS) patients (34 female), with a median age of 35 years and a median follow-up of 2.8 years. Of these, 14 patients (25.9%) experienced autoimmune AEs, in all cases dysthyroidism. No immune thrombocytopenia or nephropathies were observed.
There were no significant differences in clinical and demographic baseline characteristics (e.g. EDSS) in patients who developed autoimmune AEs versus those who did not. Patients who experienced autoimmune AEs before treatment onset did have a higher percentage of baseline blood CD19+ B cells (P=0.001), with a higher relative percentage of naïve B cells and plasmablasts. In total cell numbers, only plasmablast levels remained significant (P=0.02). Previous treatments did not significantly influence the percentage of B lymphocytes. There was a lower risk of autoimmune AEs after alemtuzumab treatment among patients with <7.6% of blood CD19+ B cells (OR 14.67; 95% CI 3.4-54.5; P<0.0001).
- Walo Delgado P, et al. Predictive biomarkers of the development of autoimmunity in patients treated with alemtuzumab. MSVirtual 2020, Abstract PS09.03.
Posted on
Previous Article
« Serum glial fibrillary acidic protein predicts relapses in NMOSD Next Article
Interrupting DMT due to pregnancy increases NfL levels »
« Serum glial fibrillary acidic protein predicts relapses in NMOSD Next Article
Interrupting DMT due to pregnancy increases NfL levels »
Table of Contents: MS Virtual 2020
Featured articles
Online First
Positive results for vagus nerve stimulation in RA
COVID-19 and MS
Biomarkers
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
Positive results for vagus nerve stimulation in RA
Neuromyelitis Optica Spectrum Disorders
Miscellaneous Topics
Related Articles
July 30, 2019
Clinical relevance of neurofilament light chain levels
November 25, 2020
Retinoid-X receptor agonist promotes remyelination
December 20, 2022
Fingolimod in paediatric MS: results of up to 6 years
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com